Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment
The purpose of this study is to test the safety of gemcitabine and oxaliplatin regimen and to see its effects on sorafenib treatment failed hepatocellular carcinoma patients.
Hepatocellular Carcinoma, Unresectable, Advanced
DRUG: Gemcitabine, Oxaliplatin
Progression free survival, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year., 1 year
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, Overall safety profile verified as relevance of adverse events and laboratory abnormality based on CTCAE v4.0., From enrollment to 30 days follow-up after the end of treatment|Response rate, Assessed by RECIST 1.1, from enrollment to 1 year follow-up after the end of treatment|Overall survival, Estimated by the Kaplan-Meier method, From enrollment to 1 year follow-up after the end of treatment
Patients who progressed after or cannot tolerate sorafenib treatment. Patients who cannot receive sorafenib for other reason are also permitted. Treatment is given in cycles, each cycle is 2 weeks long. Tumor measurements by CT and/or MRI will be repeated every 3 cycles. Patients will continue to receive study treatment as long as there is no disease progression or unacceptable side affects.